As of March 26, we're $27,100 in the red for the quarter. Donate here to support this vital work
Subscribe here and join over 13,000 subscribers to our free weekly newsletter

Fiscal Footnote: Big Senate Gift to Drug Maker
Key Excerpts from Article on Website of New York Times


New York Times, January 20, 2013
Posted: January 29th, 2013
http://www.nytimes.com/2013/01/20/us/medicare-pricing-delay-...

Just two weeks after pleading guilty in a major federal fraud case, Amgen, the worlds largest biotechnology firm, scored a largely unnoticed coup on Capitol Hill: Lawmakers inserted a paragraph into the fiscal cliff bill that did not mention the company by name but strongly favored one of its drugs. The language buried in Section 632 of the law delays a set of Medicare price restraints on a class of drugs that includes Sensipar, a lucrative Amgen pill used by kidney dialysis patients. The provision gives Amgen an additional two years to sell Sensipar without government controls. The news was so welcome that the companys chief executive quickly relayed it to investment analysts. But it is projected to cost Medicare up to $500 million over that period. Amgen, which has a small army of 74 lobbyists in the capital, was the only company to argue aggressively for the delay, according to several Congressional aides of both parties. Supporters of the delay, primarily leaders of the Senate Finance Committee who have long benefited from Amgens political largess, said it was necessary to allow regulators to prepare properly for the pricing change.

Note: For deeply revealing reports from reliable major media sources on collusion and corruption between government and the pharmaceutical industry, click here.


Latest News


Key News Articles from Years Past